Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PLCG1 | P19174 | 1/20 | 0.42 |
| ▸ | ELANE | P08246 | 7/20 | 0.41 |
| ▸ | RAB9A | P51151 | 1/20 | 0.38 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.36 |
| ▸ | HTR2A | P28223 | 1/20 | 0.36 |
| ▸ | HTT | P42858 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL337697 | 1.00 | PLCG1 (0.42) | PLCG1ELANERAB9ATDP1HTR2A | |
| SCHEMBL14153496 | 1.00 | PLCG1 (0.42) | PLCG1ELANERAB9ATDP1HTR2A | |
| SCHEMBL10013148 | 1.00 | PLCG1 (0.42) | PLCG1ELANERAB9ATDP1HTR2A | |
| SCHEMBL407970 | 1.00 | PLCG1 (0.42) | PLCG1ELANERAB9ATDP1HTR2A | |
| SCHEMBL8695596 | 1.00 | PLCG1 (0.42) | PLCG1ELANERAB9ATDP1HTR2A | |
| SCHEMBL8924773 | 1.00 | PLCG1 (0.42) | PLCG1ELANERAB9ATDP1HTR2A | |
| SCHEMBL13483984 | 1.00 | PLCG1 (0.42) | PLCG1ELANERAB9ATDP1HTR2A | |
| SCHEMBL437737 | 1.00 | PLCG1 (0.42) | PLCG1ELANERAB9ATDP1HTR2A | |
| SCHEMBL18977837 | 0.94 | PLCG1 (0.40) | PLCG1ELANERAB9AHTT | |
| SCHEMBL10013149 | 0.94 | PLCG1 (0.42) | PLCG1ELANERAB9ATDP1HTR2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2177522-B1 | NOVEL CARBAPENEM DERIVATIVES | XUANZHU PHARMA CO LTD (CN) | 2013-09-04 | — | — | EP | disclosed |
| US-8318716-B2 | Carbapenem derivatives | KBP BIOSCIENCES CO., LTD. (CN) | 2012-11-27 | — | — | US | disclosed |
| US-8293895-B2 | Carbapenem derivatives | KBP BIOSCIENCES CO., LTD. (CN) | 2012-10-23 | — | — | US | disclosed |
| US-20110160177-A1 | NOVEL CARBAPENEM DERIVATIVES | XUANZHU (HAINAN) BIOPHARMACEUTICAL CO., LTD. (CN) | 2011-06-30 | — | — | US | disclosed |
| US-20110046107-A1 | SULFONYL-SUBSTITUTED CARBAPENEM COMPOUNDS | KBP BIOSCIENCES CO., LTD. (CN) | 2011-02-24 | — | — | US | disclosed |
| US-20100197653-A1 | NOVEL CARBAPENEM DERIVATIVES | KBP BIOSCIENCES CO., LTD. (CN) | 2010-08-05 | — | — | US | disclosed |
| EP-2177522-A1 | NOVEL CARBAPENEM DERIVATIVES | KBP Biosciences Co., Ltd. (CN) | 2010-04-21 | — | — | EP | disclosed |
| EP-1686129-A1 | Carbapenems, their preparation and use the synthesis of carbapenems | Sandoz AG (CH) | 2006-08-02 | — | — | EP | disclosed |
| US-20040198973-A1 | Process for preparation of carbapenem antibiotics | EISAI CO., LTD. (JP) | 2004-10-07 | — | — | US | disclosed |
| EP-1426376-A1 | PROCESS FOR PREPARATION OF CARBAPENEM ANTIBIOTICS | Eisai Co., Ltd. (JP) | 2004-06-09 | — | — | EP | disclosed |
| US-6642377-B1 | Subjecting oxalate to salt exchange with alkali earth metal salt | EISAI CO., LTD. (JP) | 2003-11-04 | — | — | US | disclosed |
| US-6372914-B1 | Intermediates useful for the manufacture of carbapenem and a stereoselective manufacturing method therefor | EISAI CO., LTD. (JP) | 2002-04-16 | — | — | US | disclosed |
| US-6218550-B1 | MANUFACTURING (2S,4S)-2-(((R)-HYDROXY-(3R)-CYCLIC AMINE-3-YL)METHYL)PYRROLIDINE-4-THIOL OR A SALT THEREOF | EISAI CO., LTD. (JP) | 2001-04-17 | — | — | US | disclosed |
| EP-1020440-A1 | INTERMEDIATES USEFUL IN PRODUCING CARBAPENEM AND PROCESS FOR THE STEREOSELECTIVE PRODUCTION OF THE SAME | Eisai Co., Ltd. (JP) | 2000-07-19 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040198973-A1 | Process for preparation of carbapenem antibiotics | TREH, CXCL8, PCSK9 | PLCG1 4279/4885ELANE 1655/4885RAB9A 1465/4885 |
| US-20110046107-A1 | SULFONYL-SUBSTITUTED CARBAPENEM COMPOUNDS | SI, TREH, STS | PLCG1 3941/4885ELANE 983/4885RAB9A 2171/4885 |
| US-20110160177-A1 | NOVEL CARBAPENEM DERIVATIVES | MGAM, RPIA, MGAM2 | PLCG1 2209/4885ELANE 2234/4885RAB9A 1757/4885 |
| US-20100197653-A1 | NOVEL CARBAPENEM DERIVATIVES | SI, MGAM, IDE | PLCG1 2224/4885ELANE 708/4885RAB9A 1622/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.